MRSA-VAC

Towards a global vaccination approach against multi-resistant Staphylococcus aureus targeting the cellular, humoral and innate arms of the immune system

MRSA-VAC est accrédité par Lyonbiopôle

Identity card

Global budget: 2 971 k€

Public funding: 987 k€

Public funders: ANR, Agence Nationale de la Recherche

Call for projects: ANR (ANR2011 - BLANC)

Year start: 2011

Completed project


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Medical Technologies

Application fields: Infectious diseases

Technological approaches / Keywords: Immunotherapy, Innovative formulation

Stage of development at the beginning of the project: Basic research

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections represent a major Public Heath issue with important impacting socio-economical consequences. Despite all the efforts engaged, all the candidate vaccines or Abs for passive immunotherapy that have reached phase III clinical trials have failed to demonstrate statistically significant clinical benefit. There is therefore a desperate need for novel immunotherapeutic approaches and for a deeper understanding of the immunity to SA. Our project’s aim is to develop innovative immune interventions against SA and nosocomial infections.


Objectives

- To develop a novel anti-SA vaccinal strategy susceptible to confer a quick and efficient humoral protection against MRSA by targeting protein anti-SA vaccinal Ag to the thymus-independent arm of the humoral response. - To explore the immunogenicity of SA-infected cells and their recognition by different effectors of innate and adaptive cellular immunity to pave the way for an anti-SA cellular vaccine. Our ultimate goal is to boost cellular immunity against intracellular SA.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

  What we propose here is a disruptive concept of vaccination using recombinant proteins and targeting them to the T cell-independent arm of the humoral immune response by the means of antigenic particulates. The interest of our strategy extends beyond the scope of immunotherapeutics of nosocomial infections. It offers the possibility to bypass T cells and as such could be exploited for induction of protective responses in T cell immuno-compromised subjects (HIV or grafted patients for example).

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte